Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels
Background Cardiorenal syndrome type 1 is characterized by the development of acute kidney injury following acute cardiac illness and notably acute myocardial infarction (MI). Acute kidney injury is considered an independent risk factor that increases mortality rate substantially. Nicotinamide adeni...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.124.038603 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155208327299072 |
|---|---|
| author | Nada J. Habeichi Ghadir Amin Solene Boitard Cynthia Tannous Rana Ghali Iman Momken Reine Diab George W. Booz Mathias Mericskay Fouad A. Zouein |
| author_facet | Nada J. Habeichi Ghadir Amin Solene Boitard Cynthia Tannous Rana Ghali Iman Momken Reine Diab George W. Booz Mathias Mericskay Fouad A. Zouein |
| author_sort | Nada J. Habeichi |
| collection | DOAJ |
| description | Background Cardiorenal syndrome type 1 is characterized by the development of acute kidney injury following acute cardiac illness and notably acute myocardial infarction (MI). Acute kidney injury is considered an independent risk factor that increases mortality rate substantially. Nicotinamide adenine dinucleotide (NAD) is an important coenzyme in energy metabolism and oxidative phosphorylation, and in its oxidized form it is a substrate for multiple NAD+‐dependent enzymes such as sirtuins and poly‐ADP ribose polymerases. Decreased cardiac NAD levels, along with a downregulation of NAMPT (nicotinamide phosphoribosyl transferase), have been reported following MI. A compensatory upregulation in NMRK (nicotinamide riboside kinase) 2, an NAD+ biosynthetic enzyme that uses nicotinamide riboside (NR) to generate NAD+, takes place in the heart after MI, but the impact on kidney NAD metabolism and function has not been addressed before. Methods and Results MI was induced by ligating the left anterior descending coronary artery in 2‐month‐old C57BL6/J mice, followed by the administration of NR (IP injection, 400 mg/kg per day) for 4 and 7 days. We hypothesized that NR treatment could be a potentially promising therapy for MI‐induced acute kidney injury. Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post‐MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an upregulation of NAMPT‐mediated increase in renal NAD levels, notably in the distal tubules. Conclusions Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI. |
| format | Article |
| id | doaj-art-d5bd974682be4986a6c8919d2c5eb7ba |
| institution | OA Journals |
| issn | 2047-9980 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj-art-d5bd974682be4986a6c8919d2c5eb7ba2025-08-20T02:24:59ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-03-0114510.1161/JAHA.124.038603Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide LevelsNada J. Habeichi0Ghadir Amin1Solene Boitard2Cynthia Tannous3Rana Ghali4Iman Momken5Reine Diab6George W. Booz7Mathias Mericskay8Fouad A. Zouein9Université Paris‐Saclay, INSERM, Signaling and Cardiovascular Pathophysiology UMR‐S 1180 Orsay FranceDepartment of Pharmacology and Toxicology American University of Beirut, Faculty of Medicine Beirut LebanonUniversité Paris‐Saclay, INSERM, Signaling and Cardiovascular Pathophysiology UMR‐S 1180 Orsay FranceDepartment of Pharmacology and Toxicology American University of Beirut, Faculty of Medicine Beirut LebanonDepartment of Pharmacology and Toxicology American University of Beirut, Faculty of Medicine Beirut LebanonUniversité Paris‐Saclay, INSERM, Signaling and Cardiovascular Pathophysiology UMR‐S 1180 Orsay FranceDepartment of Pharmacology and Toxicology American University of Beirut, Faculty of Medicine Beirut LebanonDepartment of Pharmacology and Toxicology School of Medicine, University of Mississippi Medical Center Jackson MSUniversité Paris‐Saclay, INSERM, Signaling and Cardiovascular Pathophysiology UMR‐S 1180 Orsay FranceUniversité Paris‐Saclay, INSERM, Signaling and Cardiovascular Pathophysiology UMR‐S 1180 Orsay FranceBackground Cardiorenal syndrome type 1 is characterized by the development of acute kidney injury following acute cardiac illness and notably acute myocardial infarction (MI). Acute kidney injury is considered an independent risk factor that increases mortality rate substantially. Nicotinamide adenine dinucleotide (NAD) is an important coenzyme in energy metabolism and oxidative phosphorylation, and in its oxidized form it is a substrate for multiple NAD+‐dependent enzymes such as sirtuins and poly‐ADP ribose polymerases. Decreased cardiac NAD levels, along with a downregulation of NAMPT (nicotinamide phosphoribosyl transferase), have been reported following MI. A compensatory upregulation in NMRK (nicotinamide riboside kinase) 2, an NAD+ biosynthetic enzyme that uses nicotinamide riboside (NR) to generate NAD+, takes place in the heart after MI, but the impact on kidney NAD metabolism and function has not been addressed before. Methods and Results MI was induced by ligating the left anterior descending coronary artery in 2‐month‐old C57BL6/J mice, followed by the administration of NR (IP injection, 400 mg/kg per day) for 4 and 7 days. We hypothesized that NR treatment could be a potentially promising therapy for MI‐induced acute kidney injury. Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post‐MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an upregulation of NAMPT‐mediated increase in renal NAD levels, notably in the distal tubules. Conclusions Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI.https://www.ahajournals.org/doi/10.1161/JAHA.124.038603acute kidney injurycell deathfibrosismyocardial infarctionnicotinamide riboside |
| spellingShingle | Nada J. Habeichi Ghadir Amin Solene Boitard Cynthia Tannous Rana Ghali Iman Momken Reine Diab George W. Booz Mathias Mericskay Fouad A. Zouein Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease acute kidney injury cell death fibrosis myocardial infarction nicotinamide riboside |
| title | Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels |
| title_full | Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels |
| title_fullStr | Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels |
| title_full_unstemmed | Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels |
| title_short | Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels |
| title_sort | nicotinamide riboside a promising treatment for type 1 cardiorenal syndrome in myocardial infarction induced acute kidney injury by upregulating nicotinamide phosphoribosyltransferase mediated nicotinamide dinucleotide levels |
| topic | acute kidney injury cell death fibrosis myocardial infarction nicotinamide riboside |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.124.038603 |
| work_keys_str_mv | AT nadajhabeichi nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT ghadiramin nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT soleneboitard nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT cynthiatannous nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT ranaghali nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT imanmomken nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT reinediab nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT georgewbooz nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT mathiasmericskay nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels AT fouadazouein nicotinamideribosideapromisingtreatmentfortype1cardiorenalsyndromeinmyocardialinfarctioninducedacutekidneyinjurybyupregulatingnicotinamidephosphoribosyltransferasemediatednicotinamidedinucleotidelevels |